Anti-VEGF Treatment Strategies for Wet AMD | Zendy

Jaclyn L. Kovach | Zendy; Stephen G. Schwartz | Zendy; Harry W. Flynn | Zendy; Ingrid U. Scott | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Anti-VEGF Treatment Strategies for Wet AMD

Author(s) -

Jaclyn L. Kovach,

Stephen G. Schwartz,

Harry W. Flynn,

Ingrid U. Scott

Publication year - 2012

Publication title -

journal of ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.818

H-Index - 40

eISSN - 2090-0058

pISSN - 2090-004X

DOI - 10.1155/2012/786870

Subject(s) - medicine , macular degeneration , dosing , vegf receptors , schedule , vascular endothelial growth factor , bevacizumab , oncology , intensive care medicine , ophthalmology , chemotherapy , computer science , operating system

Over the past few years, antivascular endothelial growth factor (VEGF) therapy has become a standard treatment for neovascular age-related macular degeneration (AMD). During this time, treatment strategies have evolved from a monthly dosing schedule to individualized regimens. This paper will review the currently available anti-VEGF agents and evidence-based treatment strategies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research